Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. More Details
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Akari Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AKTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AKTX's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AKTX underperformed the US Pharmaceuticals industry which returned 5.6% over the past year.
Return vs Market: AKTX underperformed the US Market which returned 20.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Akari Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAkari Therapeutics (NASDAQ:AKTX) Will Have To Spend Its Cash Wisely
2 months ago | Simply Wall StAre Insiders Buying Akari Therapeutics, Plc (NASDAQ:AKTX) Stock?
5 months ago | Simply Wall StDoes Akari Therapeutics, Plc (NASDAQ:AKTX) Have A Volatile Share Price?
Is Akari Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AKTX ($1.57) is trading below our estimate of fair value ($18.87)
Significantly Below Fair Value: AKTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AKTX is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: AKTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AKTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AKTX is overvalued based on its PB Ratio (15.9x) compared to the US Pharmaceuticals industry average (3.6x).
How is Akari Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AKTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AKTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AKTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if AKTX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if AKTX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AKTX's Return on Equity is forecast to be high in 3 years time
How has Akari Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AKTX is currently unprofitable.
Growing Profit Margin: AKTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AKTX is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare AKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.8%).
Return on Equity
High ROE: AKTX has a negative Return on Equity (-663.25%), as it is currently unprofitable.
How is Akari Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AKTX's short term assets ($14.4M) exceed its short term liabilities ($11.1M).
Long Term Liabilities: AKTX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AKTX is debt free.
Reducing Debt: AKTX has no debt compared to 5 years ago when its debt to equity ratio was 45.1%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AKTX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AKTX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17% each year
What is Akari Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AKTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AKTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AKTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AKTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AKTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Clive Richardson (55 yo)
Mr. Clive Richardson serves as the Chief Executive Officer of Akari Therapeutics, Plc since 2019. Mr. Richardson has been the Chief Operations Officer and Director of Akari Therapeutics, Plc since Septembe...
CEO Compensation Analysis
Compensation vs Market: Clive's total compensation ($USD652.68K) is about average for companies of similar size in the US market ($USD561.84K).
Compensation vs Earnings: Clive's compensation has been consistent with company performance over the past year.
|Executive Chairman||5.17yrs||US$600.00k||0% |
|COO, CEO & Director||2.5yrs||US$652.68k||no data|
|Independent Director||4.42yrs||US$74.10k||no data|
|Independent Director||5.17yrs||US$80.01k||no data|
|Independent Director||5.17yrs||US$67.21k||0% |
|Independent Director||4.42yrs||US$69.40k||no data|
|Independent Director||2.83yrs||US$67.21k||no data|
Experienced Board: AKTX's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 83.1%.
Akari Therapeutics, Plc's company bio, employee growth, exchange listings and data sources
- Name: Akari Therapeutics, Plc
- Ticker: AKTX
- Exchange: NasdaqCM
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$60.403m
- Shares outstanding: 38.47m
- Website: https://www.akaritx.com
Number of Employees
- Akari Therapeutics, Plc
- 75/76 Wimpole Street
- Greater London
- W1G 9RT
- United Kingdom
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AKTX||NasdaqCM (Nasdaq Capital Market)||Yes||SPON ADR EACH REPR 100 ORD||US||USD||Jun 2014|
|CLAB||DB (Deutsche Boerse AG)||Yes||SPON ADR EACH REPR 100 ORD||DE||EUR||Jun 2014|
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/29 23:37|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.